Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

"The Handmaid's Tale" comes to an end after six seasons on Hulu. One of the stars, O-T Fagbenle, talks about his character and the show's cultural impact.

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.